Torrisi, S.A.; Laudani, S.; Contarini, G.; De Luca, A.; Geraci, F.; Managò, F.; Papaleo, F.; Salomone, S.; Drago, F.; Leggio, G.M.
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. Pharmaceuticals 2020, 13, 365.
https://doi.org/10.3390/ph13110365
AMA Style
Torrisi SA, Laudani S, Contarini G, De Luca A, Geraci F, Managò F, Papaleo F, Salomone S, Drago F, Leggio GM.
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. Pharmaceuticals. 2020; 13(11):365.
https://doi.org/10.3390/ph13110365
Chicago/Turabian Style
Torrisi, Sebastiano Alfio, Samuele Laudani, Gabriella Contarini, Angelina De Luca, Federica Geraci, Francesca Managò, Francesco Papaleo, Salvatore Salomone, Filippo Drago, and Gian Marco Leggio.
2020. "Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments" Pharmaceuticals 13, no. 11: 365.
https://doi.org/10.3390/ph13110365
APA Style
Torrisi, S. A., Laudani, S., Contarini, G., De Luca, A., Geraci, F., Managò, F., Papaleo, F., Salomone, S., Drago, F., & Leggio, G. M.
(2020). Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. Pharmaceuticals, 13(11), 365.
https://doi.org/10.3390/ph13110365
